BRIDGET SKINNER: Open Payments
NPI 1316117096 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,846 in 196 payments from 39 companies in 2025. Trend: 2023 $5,700 · 2024 $7,139 · 2025 $3,846
Food & beverage: $3,846
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 37 | $522 |
| EMD Serono, Inc. | 12 | $354 |
| UCB, Inc. | 18 | $330 |
| ABBVIE INC. | 17 | $273 |
| Teva Pharmaceuticals USA, Inc. | 14 | $231 |
| Neurocrine BioSciences, Inc. | 8 | $199 |
| ARGENX US, INC. | 6 | $152 |
| Axsome Therapeutics, Inc. | 5 | $119 |
| Genentech USA, Inc. | 5 | $113 |
| Alnylam Pharmaceuticals Inc. | 5 | $107 |
Products named: KESIMPTA, INGREZZA, AUSTEDO XR, Mavenclad, VYVGART HYTRULO, QULIPTA, BRIUMVI, PONVORY.
Industry payments across NY — which companies pay providers there.
